Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, describes how local health policy initiatives can help providers and patients feel more comfortable with the idea of interchangeable biosimilars.
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, describes how local health policy initiatives can help providers and patients feel more comfortable with the idea of interchangeable biosimilars.
Transcript
What policy initiatives can be adopted to ensure that concerns regarding interchangeability are mitigated and that patients are confident in the efficacy of all biosimilars?
So, I think there's policies both nationally [and] locally in our own health systems where we can drive forward the most change. And I think we need to learn from our European colleagues: How do we leverage real-world evidence so people can understand the benefits of it?
I think when we look at policies too, we recognize that with interchangeability by the FDA, not every [company is] going for it, and we recognize that it takes extra money to get an FDA approval with interchangeability.
So, how do we leverage some of our pharmacy and therapeutics policies to determine that if biosimilars are approved, we consider them equally efficacious? And that allows us to go ahead and interchange products upon dispensation with approval of the medical executive board. I think that really creates change much faster. We don't have to wait on certain therapies being interchangeable or not interchangeable, and at the end of the day, it allows us to drive consistent care.
And lastly, how do we leverage data from curative intent patient populations to noncurative intent patient populations and across different disease states, both oncology and nononcology?
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.